Section
Over-the-counter analgesic use after concussion is linked to reduced symptom severity and faster return to unrestricted play, highlighting their potential role in postconcussion management.
A 2024 multicenter study in Amhara, Ethiopia found nearly 80% of stroke survivors experienced fall-related injuries, with older age, rural residency, and walking/turning activities as key risk factors.
This multisite study identifies key clinical predictors including age, sex, BMI, diabetes, and prior neurotoxic treatments that contribute to chemotherapy-induced peripheral neurotoxicity (CIPN), affecting dose tolerance and long-term patie
Plasma pTau217 levels measured by Lumipulse G assays strongly correlate with postmortem temporal cortex pTau217 pathology, supporting plasma pTau217 as a reliable biomarker for brain tau pathology in Alzheimer disease.
Continuous ocrelizumab treatment over 10 years in relapsing MS significantly delays disability progression, reduces relapse rates, and maintains a favorable safety profile, underscoring the clinical benefit of early high-efficacy therapy.
This study clarifies that cervical cord atrophy in MS is partly disease-specific beyond aging effects, with distinct patterns linked to age and disease onset, correlating with disability and neurodegeneration markers.
Rapid whole-genome sequencing (WGS) in pediatric neurology inpatients yields nearly 50% diagnostic confirmation, significantly influencing patient management and supporting early genomic testing beyond neonatal intensive care units.
Early disclosure of plasma p-tau217 and NfL biomarkers significantly improves diagnostic confidence and clinical decisions in cognitive decline without increasing emotional distress, supporting their integration into routine memory clinic c
Early catheter ablation in atrial fibrillation patients with prior ischemic stroke reduces major adverse cardiovascular events and improves neurological and cognitive outcomes compared to medical therapy, according to a multi-center retrosp
This review synthesizes evidence on clinical and biological factors linked to discordance between plasma p-tau217 and standard AD biomarkers, highlighting implications for diagnosis, patient stratification, and future biomarker development.
This study analyzes U.S. traumatic spinal cord injury mortality trends from 1999 to 2024, revealing stable overall rates but notable demographic disparities and pandemic-related mortality increases, highlighting the need for targeted preven
A clear, clinician-focused summary of the 2026 expert consensus on designing, conducting, and analyzing prehospital stroke trials in routine EMS systems—covering patient identification, consent, trial design, endpoints, and technology prior
Early continuous creatinine changes within 48 hours after EVT correlate with graded risks of poor 90-day functional outcome and in-hospital mortality, revealing prognostic nuances beyond traditional dichotomous CA-AKI definitions.
This meta-analysis consolidates data from six RCTs comparing left atrial appendage closure (LAAC) to oral anticoagulation for stroke prevention in atrial fibrillation, highlighting reduced bleeding with LAAC but increased ischemic stroke ri
A decade-long analysis reveals a modest decline and delayed timing in withdrawal of life-sustaining treatment among patients with traumatic brain injury, highlighting evolving prognostic attitudes and clinical decision-making.
Peripheral skin nerve fiber loss correlates with cognitive impairment and brain atrophy in Parkinson disease, suggesting a peripheral-central neurodegenerative axis with potential diagnostic value.
This study assesses medium-term cognitive changes in CNS lymphoma patients treated with CAR T-cell therapy, revealing cognitive stability or improvement up to 12 months post-treatment, despite initial neurotoxicity risks.
This phase 2 trial assessed SAR443820, a RIPK1 inhibitor, in ALS patients; it showed no clinical efficacy and increased hepatic side effects, indicating limited therapeutic potential in ALS.
This article explores racial and ethnic disparities in the diagnosis, associated comorbidities, and treatment, particularly chemodenervation, among patients with facial paralysis, highlighting significant differences and healthcare gaps.
In the four-arm SleepCARE trial of 219 women receiving breast cancer chemotherapy, brief CBT-I significantly improved insomnia while bright light therapy did not beat sleep hygiene education. Neither helped fatigue, and combining the two added burden without benefit.
